Use of recombinant factor VIIa in the treatment of massive retroperitoneal bleeding due to severe necrotizing pancreatitis

• Published in: Vojnosanitetski pregled Vol. 66; no. 11; pp. 928 - 932
• Main Authors: Stefanović, Branislav, Stefanović, Branislava, Mijatović, Srdjan, Radenković, Dejan, Popović, Nada, Sijacki, Ana, Lacković, Vesna
• Format: Journal Article
• Language: English
• Published: Serbia Military Health Department, Ministry of Defance, Serbia 01-11-2009
• Subjects: digestive system surgical procedures; factor VIIa; Factor VIIa - therapeutic use; hemorrhage; Hemorrhage - drug therapy; Hemorrhage - etiology; Hemostatics - therapeutic use; Humans; Male; Middle Aged; pancreatitis; Pancreatitis, Acute Necrotizing - complications; Recombinant Proteins - therapeutic use; Retroperitoneal Space
• ISSN: 0042-8450; 2406-0720
• DOI: 10.2298/VSP0911928S

Recently, a growing number of case reports and case series have suggested that the use of recombinant activated factor VII (rFVIIa) may be effective in treatment of patients with non-hemophilic acquired coagulopathy not responding to conventional treatment such as major surgery, major trauma, sepsis, necrotizing pancreatitis and bleeding due to cerebral arteriovenous malformations.
We presented a septic patient with massive, life-threatening bleeding caused by retroperitoneal necrosis, due to severe acute necrotizing pancreatitis. As conservative treatment (blood, plasma, cryoprecipitates and platelet transfusions) failed to induce cessation of bleeding, the patient was urgently operated on. In spite of usual procedures of surgical hemostasis (ligation, suture, thermocauterisation, fibrin glue, temporary tamponade), hemorrhage could not be stopped. The patient manifested the signs of hypothermia and metabolic acidosis and, therefore, the decision was made to use recombinant activated factor VII (Novo Seven). The application of rFVIIa resulted in significant discontinuation of hemorrhage, restoration to normal blood count as well as other relevant coagulation parameters.
Although application of rFVIIa is still in the initial clinical phase, and the experience is based mainly on uncontrolled series as well as on individual observations, it seems that this drug can be promising, potent and attractive adjunctive prohemostatic agent. This drug may play a beneficial role in the treatment of serious and unresponsive, "nonsurgical", life-threatening bleeding due to severe acute necrotizing pancreatitis.